BRCA2 Mutation in Jewish Patients with GI Cancers
Author Information
Author(s): Figer A, Irmin L, Geva R, Flex D, Sulkes J, Sulkes A, Friedman E
Primary Institution: Institute of Oncology, Epidemiology Unit, Rabin Medical Center
Hypothesis
Does the 6174delT mutation in BRCA2 contribute to non-colonic gastrointestinal cancers in Jewish Israeli patients?
Conclusion
The BRCA2 mutation rate in patients with gastric and pancreatic cancer is significantly higher than in the general Ashkenazi population.
Supporting Evidence
- 6 mutation carriers were detected among the patients tested.
- 13% of pancreatic cancer patients carried the mutation.
- 5.7% of gastric cancer patients carried the mutation.
- 25% of bile duct cancer patients carried the mutation.
- The mutation carrier rate among patients is significantly higher than the general Ashkenazi population.
Takeaway
Some Jewish people have a specific gene change that makes them more likely to get certain stomach and pancreas cancers.
Methodology
PCR amplification and modified restriction enzyme digests were used to test for the mutation.
Participant Demographics
Jewish Ashkenazi patients aged 38–90 years, mean age 65.8 years.
Statistical Information
P-Value
0.0002
Statistical Significance
p=0.0002
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website